NDATRANSDERMALSYSTEM
Approved
Oct 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
CATAPRES-TTS-1 (clonidine transdermal system) by Lavipharm is adrenergic alpha2-agonists [moa]. Approved for central alpha-2 adrenergic agonist [epc]. First approved in 1984.
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CATAPRES-TTS-1 is a transdermal clonidine system delivering central alpha-2 adrenergic agonist therapy for hypertension management. The drug works by stimulating alpha-2 receptors in the central nervous system to reduce sympathetic outflow and lower blood pressure. Patients receive continuous drug delivery via a patch-based formulation applied to the skin.
LOE Approaching
LOE-approaching lifecycle with low competitive pressure (30%) suggests a mature, stable brand team focused on retention and generic defense rather than growth.
Mechanism of Action
Adrenergic alpha2-Agonists
Pharmacologic Class:
Central alpha-2 Adrenergic Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CATAPRES-TTS-1 offers experience in mature product management, generic defense, and payer negotiations in a declining market. Career growth is limited unless you transition into adjacent roles such as portfolio strategy, product lifecycle extension, or managed care—making this a consolidation-focused opportunity rather than a launch-growth career accelerator.
Brand Manager
Worked on CATAPRES-TTS-1 at Lavipharm? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.